A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
Inferred to overlap with: Df(2R)BSC661.
The presence of P+PBac{XP5.RB3}BSC778 was verified using the PCR methods and primers described in FBrf0175003, with the substitution of the primer 5'-CCAATGCGTTTATTTCAGGTCACG-3' for the RB3' plus or RB3' minus primer in the Hybrid PCR protocol in the Supplementary Methods.
Exelixis, Inc. determined the insertion site of the progenitor PBac{RB}e02152 to be Release 3 genomic coordinate 18357358 on chromosome arm 2R. This corresponds to Release 5 coordinate 2R:19201313 . The insertion site of the progenitor P{XP}CG3530d07361 is Release 5 genomic coordinate 2R:19283437 . Consequently, the breakpoints of Df(2R)BSC778 predicted from the Release 5 genomic coordinates of the transposable element insertion sites are 2R:19201313 ;19283437 and the cytological breakpoints predicted from these coordinates are 59D6;59D10.